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long-term prognostic value of functional status assessment
in stable patients with chronic HF.
Methods
Study Population
The Cleveland Clinic Genebank study prospectively enrolled a
total of 8,987 subjects who underwent coronary angiography in
the absence of an acute coronary syndrome, without a history
of revascularization within 30 days before enrollment, and
$5 years of long term adjudicated follow up data. Detailed med
ical histories were obtained on all subjects (predominantly outpa
tients) at enrollment. Blood samples were collected at the time of
cardiac catheterization after arterial sheath placement, but before
the catheterization procedure or any therapy (including anticoagu
lation medications). Every participant gave written informed con
sent approved by the Institutional Review Board.
Data Collected
The present analysis included 1,700 of consecutive subjects
with a medical history of HF with reduced or preserved left ven
tricular ejection fraction (LVEF) enrolled in Genebank, who
completed the DASI questionnaire (Table 1) and with correspond
ing blood samples for analysis. Chronic HF was deﬁned as a docu
mented history of HF by treating physician in the electronic
medical record and conﬁrmed by study personnel at the time of
enrollment. Heart failure was deﬁned as a documented history
of HF by the treating cardiologist in the electronic medical record
at the time of enrollment.
Biomarkers and Echocardiography
B Type natriuretic peptide (BNP), creatinine, fasting lipid
proﬁles, cardiac troponin I (TnI), uric acid, and high sensitivity
C reactive protein (hs CRP) were measured on the Abbot Architect
platform (Abbott Laboratories, Abbot Park, Illinois). An estimate of
glomerular ﬁltration rate (eGFR) was calculated with the use of the
Modiﬁcation of Diet in Renal Disease equation. LVEF was deter
mined via transthoracic echocardiography by the Cleveland Clinic
echocardiography laboratory reviewed by Board certiﬁed cardio
logists with the use of chart review of the electronic medical record.
Adjudicated outcomes were prospectively ascertained over the
ensuing 5 years for all subjects after enrollment.
DASI Questionnaire
Patients were asked to complete the DASI survey, supervised by
study personnel, at the time of coronary angiography. The DASI is
a self administered questionnaire that measures both functional
capacity and quality of life aspects. It correlates well with peak
oxygen uptake on stress testing.5 The survey attempts to capture
major aspects of physical function: personal hygiene, ambulation,
routine tasks, recreation, and sexual function. High scores corre
late with better functional capacity. This questionnaire has been
validated in similar populations.7,8
Statistical Analysis
This cohort was split into quartiles of DASI score for the pop
ulation. P values of #.05 were considered to be signiﬁcant to
reject the null hypothesis that there were no differences in mortal
ity at 5 years of follow up between the highest and lowest DASI
score quartiles. Independent variable was DASI score quartile,
and dependent variable was mortality at 5 years. Parametric and
nonparametric approaches were used to express continuous vari
ables. Survival analyses were completed with the use of the
Kaplan Meier method and log rank analysis to compare survival
curves among the 4 quartiles. Cox proportional hazards models
were used to compare time to event analyses to determine hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) for 5 year morta
lity between the 1st and 4th quartiles of DASI scores. Multivariate
models were adjusted for traditional cardiac risk factors, including
age, sex, systolic blood pressure, cigarette smoking, history of dia
betes, and fasting low density lipoprotein and high density lipo
protein cholesterol levels. Additional adjustments were made for
a subset with both measured BNP and eGFR values. Subgroups
were divided according to age $60 years, LVEF !45%, eGFR
!60 mL min1 1.73 m2, history of coronary artery disease
(CAD), TnI $0.03 ng/mL, sex, uric acid $9.8 mg/dL, hs
CRP $2 mg/dL, history of diabetes mellitus, and history of
chronic obstructive pulmonary disease (COPD). Statistical ana
lyses were performed with the use of JMP Pro version 9 (SAS
Institute, Cary, North Carolina).
Results
Baseline characteristics are described in Table 2 and are
representative of a patient population with chronic HF. The
reasons for cardiac catheterization within the study cohort
were as follows (subjects can have O1 reason): history of
positive or abnormal stress test (30%), evaluation for
possible ischemic causes of symptoms (63.5%), preopera-
tive evaluation (24%), and history of cardiomyopathy
(14%). DASI surveys were successfully completed by
1,700 study participants, and scores across this study cohort
were nonparametrically distributed (Fig. 1). The median
DASI score was 26.2 (interquartile range 15.5 42.7). The
mean DASI scores for quartiles 1 4 were 8.7 6 3.7,
20.2 6 3.2, 33.4 6 3.9, and 50.0 6 5.9, respectively.
Decreasing DASI scores were associated with increasing
comorbidity (Table 2), but not with LVEF (P 5 .4). There
were no differences in either angiotensin-converting
Table 1. Duke Activity Status Index (DASI)
Can You: Weight
Take care of yourself, that is, eat, dress, bathe, or use the toilet? 2.75
Walk indoors, such as around your house? 1.75
Walk a block or two on level ground? 2.75
Climb a ﬂight of stairs or walk up a hill? 5.50
Run a short distance? 8.00
Do light work around the house like dusting or washing dishes? 2.70
Do moderate work around the house like vacuuming, sweeping
ﬂoors, or carrying groceries?
3.50
Do heavy work around the house like scrubbing ﬂoors or lifting
or moving heavy furniture?
8.00
Do garden work like raking leaves, weeding, or pushing a lawn
mower?
4.50
Have sexual relations? 5.25
Participate in moderate recreational activities like golf,
bowling, dancing, doubles tennis, or throwing a ball?
6.00
Participate in strenuous sports like swimming, singles tennis,
football, basketball, or skiing?
7.50
Range: 0 (worst) to 58.2 (best).
enzyme inhibitor (ACEI)/angiotensin receptor blocker
(ARB) or beta-blocker use across DASI quartiles
(P values .2 and .8, respectively).
Predicting Mortality Risk With DASI Score
In our study cohort, 1,692 study participants were fol-
lowed for all-cause mortality over 5 years after study entry.
By 5 years there were a total of 556 deaths and 1,023 sub-
jects survived to the end of follow-up. 113 study partici-
pants were lost to follow-up. Kaplan-Meier estimates of
survival were calculated for 1,692 participants (Fig. 2).
The estimated 5-year survival rate was 67%. DASI score
quartiles 1 4 had 193, 166, 120, and 77 deaths, respec-
tively, by the end of follow-up. There were signiﬁcant dec-
rements in survival across increasing DASI score quartiles:
log-rank chi-square 96.1; P ! .0001. The lowest DASI
score quartile predicted a 3.3-fold increase in risk of
5-year mortality compared with the highest DASI score
quartile: HR 3.33, 95% CI 2.57 4.36; P ! .0001;
Table 3). After additional adjustment for traditional risk
factors, lower DASI scores still independently predicted
an increased risk for death: HR 2.78, 95% CI 2.10 3.72;
P ! .0001. Furthermore, when stratifying DASI score by
median (26.2), in addition to multivariate adjustment for
traditional risk factors, the area under the receiver operating
characteristic curve for 5-year mortality was 69.4%. In a
sensitivity analysis with multivariate adjustment for LVEF
in addition to traditional risk factors, lower DASI scores re-
mained predictive of increased mortality: HR 2.79, 95% CI
2.10 3.72; P! .0001. Compared with DASI scoresO40,
DASI scores #40 predicted a 2-fold increased risk for
death: HR 2.00, 95% CI 1.58 2.58; P ! .0001. Subgroup
analyses reveal that DASI scores predict all-cause mortality
across dichotomized subgroups of age, sex, history of coro-
nary artery disease, history of diabetes mellitus, history of
COPD, eGFR, and LVEF (Fig. 3)
Prognostic Value of DASI Adjusting for Cardiorenal
Biomarkers
In a subset of patients with available BNP data (Fig. 4) at
the time of the DASI questionnaire, we observed only a
Fig. 1. Duke Activity Status Index (DASI) score distribution in
study cohort (n 5 1,700).
Fig. 2. Kaplan Meier estimates of 5 year survival rates according
to Duke Activity Status Index (DASI) score.
Table 2. Baseline Characteristics
Variable
DASI Score Quartile
P Value!15.5 15.5e26.1 26.2e42.7 O42.7
Age (y) 68 6 11 69 6 11 66 6 11 64 6 11 !.0001
Male (%) 45.4 60.0 72.6 81.0 !.0001
BMI (kg/m2) 29.8 (25.9e35.1) 28.4 (24.8e33.3) 28.1 (25.2e32.3) 28.9 (25.5e32.3) .001
Diabetes mellitus (%) 49.3 44.4 35.8 27.2 !.0001
Hypertension (%) 83.0 80.0 79.3 78.2 .4
Coronary artery disease (%) 80.3 75.4 77.3 69.7 .003
Smoking history (%) 66.6 72.1 74.3 75.2 .03
LVEF (%) 45 (30e55) 40 (25e55) 40 (25e55) 40 (29e55) .4
BNP (pg/mL) 457 (155e971) 337 (136e781) 316 (119e639) 205 (86e411) !.0001
eGFR (mL min 1 1.73 m 2) 56.1 (41.9e74.0) 57.1 (42.8e74.1) 59.0 (46.8e75.0) 61.7 (49.9e76.0) .001
Beta blocker (%) 66.8 68.0 68.0 65.2 .8
ACEI/ARB (%) 63.9 67.7 68.8 70.5 .2
Loop diuretic (%) 68.1 69.3 55.2 40.7 !.0001
DASI, Duke Activity Score Index; BMI, body mass index; LVEF, left ventricular ejection fraction; BNP, B type natriuretic peptide; eGFR, estimated
glomerular ﬁltration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Values are presented as either mean 6 SD or median (interquartile range) unless otherwise stated. P values were calculated with the use of analysis of
variance or Kruskall Wallis test for continuous variables and chi square method for categoric variables.
modest correlation between BNP (Spearman rho 5 0.210;
P ! .0001) and DASI score. Estimated glomerular ﬁltra-
tion rate was also modestly correlated with DASI score
(Spearman rho 5 0.107; P ! .0001) for the total cohort.
Lower DASI scores still independently predicted an
increased risk for death after adjusting for traditional risk
factors, BNP, and eGFR: HR 2.57, 95% CI 1.64 4.15;
P ! .0001).
Discussion
There are several key ﬁndings in our study. First, we sur-
veyed a large cohort of patients with chronic stable HF un-
dergoing elective coronary evaluation and observed an
association between lower functional status (as measured
with the use of the DASI questionnaire) and greater risk
of 5-year mortality. Second, this association remained robust
after multivariate adjustment for traditional cardiac risk fac-
tors and, in a subset of patients, after additional adjustment
for cardiorenal biomarkers. Although commonly attributed
to the underlying comorbid conditions, the association be-
tween diminished functional capacity and 5-year all-cause
mortality appeared to be consistent across a variety of sub-
groups of patients with different comorbid conditions and
clinical characteristics. Taken together, these ﬁndings illus-
trate the potential of patient-centric insight gained by con-
ducting a simple questionnaire developed to assess overall
functional capacity.
Functional capacity is an important component of a
patient-centric evaluation of HF, and recommendations
for its careful assessment have been included in the latest
clinical management guidelines.9,10 Although the DASI
Table 3. Cox Proportional Hazards Model for Risk of 5
Year Mortality Stratiﬁed According to DASI Scores
Model HR 95% CI P Value
Univariate 3.33 2.57e4.36 !.0001
Multivariate
Adjusted for traditional risk
factors*
2.78 2.10e3.72 !.0001
Adjusted for traditional risk
factors* þ BNP þ eGFRy
2.57 1.64e4.15 !.0001
HR, hazard ratio; CI, conﬁdence interval; other abbreviations as in
Table 2.
Quartile 1 versus quartile 4.
*Traditional risk factors included age, sex, systolic blood pressure, his
tory of diabetes, smoking, low density lipoprotein cholesterol, and high
density lipoprotein cholesterol.
ySubset of 800 subjects with biomarker data available.
Fig. 3. Subgroup analysis of Duke Activity Status Index (DASI) score and 5 year mortality. HR, hazard ratio; CI, conﬁdence interval; EF,
ejection fraction; eGFR, estimated glomerular ﬁltration rate; CAD, coronary artery disease; TnI, troponin I; hs CRP, high sensitivity C
reactive protein; COPD, chronic obstructive pulmonary disease.
was developed O20 years ago,5 its application has been
largely restricted as a subjective assessment tool in clinical
trials. The DASI is a simple self-administered questionnaire
that assesses perceived functional status. Rather than
relying on recall, it is composed of questions relating to
self-assessment of one’s ability to perform activities that
represent major aspects of physical function. Set up as a
continuous measure, DASI scores correlate with peak oxy-
gen uptake during cardiopulmonary stress testing.5 The
DASI has been validated in cohorts of patients with HF,
obstructive CAD, and COPD.5,11,12 Although the accuracy
of DASI score in predicting peak oxygen uptake in the
setting of HF has been challenged,8,13 our ﬁndings support
the notion that the clinical utility may likely extend beyond
performance on stress testing. Indeed, a recent comparison
of several commonly used objective assessments of func-
tional capacity did not validate cardiopulmonary exercise
stress testing as equivalent to other, simpler, forms of exer-
cise capacity evaluation, such as the 6-minute walk test, in
terms of prognostic utility.14
To our knowledge, this is the largest cohort of patients
with HF who have completed the DASI survey and have
been followed longitudinally for adverse outcomes. Our
ﬁndings conﬁrm several smaller studies that have suggested
the prognostic value of functional status assessment in the
setting of HF. For example, DASI scores were lower in a
population of 130 patients with impaired LVEF recently
hospitalized for decompensated HF who experienced
adverse events after 9 months of follow-up compared
with those that did not.6 Paired with BNP, those with low
DASI scores and higher BNP levels were more likely to
have lower event-free survival.6 In adults O75 years old,
lower functional status, as measured with the use of the pre-
admission Barthel Index, was a strong predictor of 3-month
mortality.15 In the setting of cardiac surgery, lower DASI
scores have also been associated with higher mortality
risk,16 and changes in DASI scores have been observed af-
ter surgery.17 It has been suggested that DASI scoring may
vary based on factors that affect functional capacity, such as
age, sex, COPD, and the presence of diabetes mellitus.18
Yet, based on our ﬁndings, its prognostic value in these
cohorts remained robust. Additionally, we found that
DASI scores correlate with mortality in patients with either
reduced or preserved left ventricular function and were not
related to systematic differences (eg, ACEI/ARB or beta-
blocker use) in medical management of HF.
There are other prognostic instruments that capture func-
tional status as well. In a cohort of 6,975 outpatients with
chronic HF from the Gruppo Italiano per lo Studio Della
Streptochinasi Nell’Infarto Miocardico Heart Failure Trial
(GISSI-HF), New York Heart Association (NYHA) func-
tional classiﬁcation III or IV was independently associated
with a more adverse prognosis than NYHA functional clas-
siﬁcation II.19 NYHA functional class is a simple score
ordinally assessing exertional symptoms in HF. Yet it has
notable limitations1: no consistent assessment method
and1 high interoperator variability.20 The Minnesota Living
With Heart Failure Questionnaire (MLHFQ) is a validated
HF-speciﬁc questionnaire based on a Likert scale.21 Data
from the Irbesartan in Heart Failure With Preserved
Ejection Fraction Study (I-PRESERVE) suggests that lower
MHLF scores are associated with adverse outcomes in pa-
tients with HF with preserved LVEF.22 In contrast to these
scores, the DASI can provide a continuum of scores, and is
easily administered with simple yes/no patient responses,
either oral or written.
Increasing plasma levels of natriuretic peptides have
been associated with adverse outcomes in chronic HF23
and may provide incremental prognostic information inde-
pendently from clinical assessment.24 Furthermore, based
on an ancillary study from the Studies on Left Ventricular
Dysfunction (SOLVD) trial, worsening renal function is
independently associated with both mortality and disease
progression in patients with LV dysfunction.25 Renal func-
tion also provides additional prognostic information in pa-
tients with HF independently from functional status as
measured by the 6-minute walk test.26 Our observation
regarding the incremental prognostic value of DASI after
inclusion of BNP and eGFR in multivariate adjustment sug-
gested that factors incremental to cardiorenal disease pro-
gression that are captured by the patient’s own perception
of his or her own functional status may affect long-term
outcomes. For example, other underlying metabolic de-
rangements or physical limitations may be uncovered dur-
ing DASI assessment.
Our results must be interpreted in the context of several
limitations in our study design. Because DASI scores were
measured at only 1 point in time, we were unable to
examine the variability and prognostic value of changing
DASI scores over time or the impact of different therapies
in the interim. Furthermore, baseline NYHA functional
class was unavailable and hospitalization readmissions
were not adjudicated. We cannot exclude the presence of
unmeasured confounding by baseline depressive symptoms,
because these were not assessed on study inclusion, or se-
lection bias for those undergoing coronary angiography
for further evaluation and management of HF at a ter-
tiary care center, although based on baseline clinical
Fig. 4. Median B type natriuretic peptide (BNP) by Duke Activity
Status Index (DASI) score (n 5 819).
characteristics they appear to be relatively representative of
a contemporary patient population with HF. However, the
majority of the patients in this analysis had ischemic car-
diomyopathy and there was low use of beta- and renin-
angiotensin blocking agents. Nevertheless, based on our
promising results and in the era where patient-centric out-
comes are valued, further investigations into the clinical
utility of baseline and serial DASI questionnaire adminis-
trations are warranted.
Conclusion
In patients with stable HF, functional status assessment,
as measured by the DASI questionnaire, predicts mortality
at 5 years. This assessment provides independent and addi-
tional prognostic information beyond the measurement of
BNP and eGFR. Lower DASI scores predict mortality
across a variety of subgroups of differing prognosis in pa-
tients with HF. These results highlight the importance of as-
sessing functional status in patients with HF. Future studies
using functional status assessment as a tool for treatment
intensiﬁcation in HF are warranted.
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